gesunheitpfleges.org



Champions Biotechnology is now Champions Oncology

March 10, 2016

TMI's TTP was originally isolated from scorpion venom. The peptide was identified and pursued experimentally based on its ability to specifically bind and suppress growth of activated epithelial cells. Subsequent studies have found the peptide and engineered variants can bind be internalized by malignant cells via the annexin A2 complex.

"The acquisition of these TMI assets by Morphotek is an excellent outcome for TMI's investors, who will directly receive proceeds and potential future milestone payments from this transaction.  We have great confidence in Morphotek's ability to develop innovative therapies created from TMI's broadly enabling platform technology, and we look forward to seeing these therapies benefit patients," added Curt LaBelle, Director of the Board of TMI."

The transaction provides Morphotek and Eisai exclusive ownership of TTP for therapeutic and diagnostic uses.  Morphotek intends to pursue the TTP platform through collaboration with other EPCS units to develop TTP conjugates for treating a variety of different cancers.

SOURCE Morphotek, Inc.